, chemotherapy continues to be used widely for now. This may be attributed to the fact that the use of targeted therapy is limited due to access and affordability issues, thereby making those complements rather than substitutes for chemotherapy. "Due to higher cost compared to cytotoxic and hormonal therapies, the use of targeted therapies in Australia is and will continue to be largely dependent on their price and availability on the Pharmaceutical Benefits Scheme (PBS)," says Gaffud.
Currently, only Herceptin (for early stage breast cancer patients) and Tykerb (for advanced/metastatic breast cancer patients) are subsidized through the PBS. Nonetheless, innovative targeted therapies are showing great promise and are being touted as the future of breast cancer treatment. Combinations of these highly specific therapies with existing cytotoxic and hormonal therapies will soon become the standard of oncology care.
Frost & Sullivan's latest research service on The Breast Cancer Therapeutics Market in Australia provides competitive structure, market analysis and future trends for the breast cancer drug therapies (cytotoxic, hormonal and targeted) in Australia.
This analysis is available through our Pharmaceutical & Biotechnology Growth Partnership Services programme. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services programme ensures that you and your Growth Team(TM) are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadePage: 1 2 3 Related biology technology :1
. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens2
. Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial3
. Monitoring Circulating Tumor Cells With the CellSearch(R) System Can Predict Prognosis in Metastatic Breast Cancer4
. New MRI technique could mean fewer breast biopsies in high-risk women5
. Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer6
. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer7
. DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 8
. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting9
. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting10
. Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting11
. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial